Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Adriana Kajon"'
Autor:
Marina S. Boukhvalova, Emma Mortensen, Jessica Caple, John Joseph, Fatoumata Sylla, Arash Kamali, Daniel Stylos, Diego Lopez, Thomas March, Kevin Matthew Byrd, Gregory A. Prince, Ariel Arndt, Adriana Kajon, Jorge C. G. Blanco
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Heterogeneity of COVID-19 manifestations in human population is vast, for reasons unknown. Cotton rats are a clinically relevant small animal model of human respiratory viral infections. Here, we demonstrate for the first time that SARS-CoV-
Externí odkaz:
https://doaj.org/article/c6aa0ff1820c498eafdc7b35ad72ded1
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 5, Pp 1047-1049 (2020)
Human adenovirus 7d is a respiratory pathogen capable of causing acute respiratory disease of variable severity. Phylogenetic analysis of whole-genome sequences of 15 strains isolated from cases of influenza-like-illness during 2017–2019 demonstrat
Externí odkaz:
https://doaj.org/article/38e02e555d4b406a8e40cacc1197ab01
Autor:
Débora N Marcone, Andrés C A Culasso, Noelia Reyes, Adriana Kajon, Diana Viale, Rodolfo H Campos, Guadalupe Carballal, Marcela Echavarria
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0248191 (2021)
Human adenoviruses (HAdV) are one of the most frequent causes of respiratory infections around the world, causing mild to severe disease. In Argentina, many studies focused on the association of HAdV respiratory infection with severe disease and fata
Externí odkaz:
https://doaj.org/article/b4d152fe08414e91abd68c28351a90cd
Autor:
Jared Pitts, Darius Babusis, Meghan S. Vermillion, Raju Subramanian, Kim Barrett, Diane Lye, Bin Ma, Xiaofeng Zhao, Nicholas Riola, Xuping Xie, Adriana Kajon, Xianghan Lu, Roy Bannister, Pei-Yong Shi, Maria Toteva, Danielle P. Porter, Bill J. Smith, Tomas Cihlar, Richard Mackman, John P. Bilello
Publikováno v:
Antiviral Research. 203:105329
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir (RDV, VEKLURY®) is currently the only antiviral therapy fully approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59eb2e0e7c1a5b5a82c2d5e6c79f53a6
https://doi.org/10.1016/j.antiviral.2022.105329
https://doi.org/10.1016/j.antiviral.2022.105329